Literature DB >> 15351346

New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections.

Michael J Otto1.   

Abstract

Several new nucleoside analogs are currently in development for the treatment of HIV-1 infections. Alovudine, amdoxovir, elvucitabine, Racivir, Reverset and SPD 754 are nucleoside reverse transcriptase inhibitors that were designed and selected in anticipation of having improved resistance, safety, compatibility and efficacy profiles. Clinical trials are demonstrating that some of these goals are being met, and that nucleoside analogs as a class of compounds remain fertile ground for finding valuable additions to current anti-retrovirus treatment regimens.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15351346     DOI： 10.1016/j.coph.2004.06.001

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  9 in total

1.  Synthesis and Biological Evaluation of 5'-O-Dicarboxylic Fatty Acyl Monoester Derivatives of Anti-HIV Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Bhanu Pemmaraju; Hitesh K Agarwal; Donghoon Oh; Karen W Buckheit; Robert W Buckheit; Rakesh Tiwari; Keykavous Parang
Journal:  Tetrahedron Lett       Date:  2014-03-19       Impact factor: 2.415

2.  Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug.

Authors:  Ana C Venhoff; Dirk Lebrecht; Frank U Reuss; Brigitte Heckl-Ostreicher; Roland Wehr; Ulrich A Walker; Nils Venhoff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

3.  Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.

Authors:  Philippe Colucci; John C Pottage; Heather Robison; Jacques Turgeon; Dirk Schürmann; I M Hoepelman; Murray P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

4.  Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

Authors:  Tomas Cihlar; Adrian S Ray; Constantine G Boojamra; Lijun Zhang; Hon Hui; Genevieve Laflamme; Jennifer E Vela; Deborah Grant; James Chen; Florence Myrick; Kirsten L White; Ying Gao; Kuei-Ying Lin; Janet L Douglas; Neil T Parkin; Anne Carey; Rowchanak Pakdaman; Richard L Mackman
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191

Review 5.  Pharmacologic aspects of new antiretroviral drugs.

Authors:  Mary C Long; Jennifer R King; Edward P Acosta
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.495

6.  Pharmacologic aspects of new antiretroviral drugs.

Authors:  Mary C Long; Jennifer R King; Edward P Acosta
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.663

7.  Antiretroviral drugs: critical issues and recent advances.

Authors:  Mira Desai; Geetha Iyer; R K Dikshit
Journal:  Indian J Pharmacol       Date:  2012-05       Impact factor: 1.200

Review 8.  Synthesis of Spironucleosides: Past and Future Perspectives.

Authors:  Raquel G Soengas; Gustavo da Silva; Juan Carlos Estévez
Journal:  Molecules       Date:  2017-11-22       Impact factor: 4.411

9.  The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.

Authors:  Dana Yehudai; Sanduni U Liyanage; Rose Hurren; Biljana Rizoska; Mark Albertella; Marcela Gronda; Danny V Jeyaraju; Xiaoming Wang; Samir H Barghout; Neil MacLean; Thirushi P Siriwardena; Yulia Jitkova; Paul Targett-Adams; Aaron D Schimmer
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.